![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre (Québec, Canada) is an academic organization dedicated to advancing knowledge and promoting discoveries in personalized medicine by leading high-quality pharmacogenomic research in partnership with industrial, governmental and academic organizations. Since its establishment in 2008, the Centre has been leading innovative genomics research programs for all phases of drug development and has conducted over 120 pharmacogenomic projects through collaborations with international partners using state-of-the-art platforms with the highest-quality data. The Centre has a fully equipped DNA and genomic laboratory facility, supported by bioinformatics, statistical genetics, quality assurance and project management teams. More recently, the Centre has partnered with the Centre of Excellence in Personalized Medicine for the commercialization of biomarkers and implementation in clinical practice, and with the Montreal Health Innovations Coordinating Centre for study coordination and integration with drug development pipelines. Through its academic excellence, unique expertise in Canada and international industrial partners, the Pharmacogenomics Centre is providing the technologies and research discoveries needed to provide the right therapy to the right patients.
Acknowledgements
The authors gratefully acknowledge the dedicated efforts and vision of all who have been involved in creating the Pharmacogenomics Centre.
Financial & competing interests disclosure
The Pharmacogenomics Centre was funded in part from grants from Genome Canada, Genome Québec, the Canadian Foundation for Innovation, the MHI Foundation, and private donations from M Saucier and G Beaulieu. The Pharmacogenomics Centre has entered into partnership agreements and service contracts with Pfizer, Servier, Merck Frost, Hoffmann-La Roche, AstraZeneca, VIA Pharmaceuticals, Hema-Québec, the Public Health Agency of Canada, Xenon Pharmaceutical, AutoGenomics and Spartan Biosciences. The authors are employees of The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.